Treating brain cancer where it grows
Curatio Therapeutics develops therapies that use intranasal delivery to reach the brain directly. Our lead program, LMP01, targets glioblastoma, the most aggressive primary brain cancer in adults.
Learn about LMP01View pipelineThe problem
Glioblastoma has seen little progress in two decades. With standard treatment, median survival is about 15 months, fewer than 1 in 10 patients are alive five years after diagnosis, and nearly all tumors come back. Options at recurrence are limited.
A central obstacle is the blood-brain barrier, which keeps most drugs from reaching brain tumors at effective levels. The same barrier limits treatment of brain metastases, leptomeningeal disease and other CNS cancers.
LMP01 at a glance
A combination of two small molecules acting on two pathways glioblastoma depends on, delivered intranasally and designed to bypass the blood-brain barrier.
FDA Orphan Drug Designation
Granted for LMP01 in malignant glioma, which includes glioblastoma.
Dual mechanism
Targets tumor energy metabolism and RAS and cell-cycle signaling at the same time.
Human signal
A patient with IDH wild-type glioblastoma, whose compassionate use treatment included both compounds in LMP01, survived more than ten years with a good quality of life.
Beyond glioblastoma
The same combination and the same route of delivery may apply to other cancers of the central nervous system. Following proof of concept in glioblastoma, we plan to explore recurrent high-grade gliomas, brain metastases, leptomeningeal disease, primary CNS lymphoma and pediatric high-grade gliomas.
How we work
We run a lean development model. Every program and indication must pass clear go and no-go decisions early, and we stop work on candidates that do not show a realistic path to patients. That discipline lets us concentrate capital and talent where the evidence is strongest.
“Innovation is seeing what everybody has seen and thinking what nobody has thought.”
Albert Szent-Györgyi, Nobel Prize in Physiology or Medicine, 1937
Work with us
We welcome conversations with clinical investigators, research partners and collaborators in neuro-oncology.
Get in touch